Introduction {#s1}
============

Members of the transforming growth factor β (TGF-β) family of ligands, which includes the TGF-βs, Activins, NODAL, BMPs and GDFs, have pleiotropic effects on cell behavior ranging from germ layer specification and patterning in embryonic development, to tissue homeostasis and regeneration in adults ([@bib42]; [@bib49]; [@bib76]). TGF-β family signaling is also deregulated in a number of human diseases through mutation or altered expression of either the ligands or downstream signaling pathway components ([@bib46]). In this context, the most widely studied pathology is cancer ([@bib3]; [@bib41]; [@bib43]; [@bib70]), where TGF-β itself has both tumor suppressive and tumor promoting effects ([@bib41]). At early stages of cancer TGF-β's tumor suppressive effects dominate, such as its cytostatic and pro-apoptotic functions ([@bib54]). As tumors develop, however, mutations in key components of the pathway or downstream target genes allow the tumor to evade TGF-β's tumor suppressive effects, whilst remaining sensitive to its tumor-promoting activities. TGF-β directly promotes the oncogenic potential of tumor cells, for example by driving epithelial-to-mesenchymal transition (EMT), a hallmark of cancer that enhances cell invasion and migration, and also increases the frequency of tumor-initating cancer stem cells ([@bib41]; [@bib77]). TGF-β's dual role in cancer thus provides an excellent example of how diverse responses can be elicited by a single ligand.

The TGF-β family ligands all signal via a common mechanism, initiated by ligand binding to two cell surface serine/threonine kinase receptors, the type II and type I receptors. In the receptor complex, the type II receptors phosphorylate and activate the type I receptors ([@bib73]). These in turn phosphorylate the downstream effectors of the pathway, the receptor-regulated SMADs (R-SMADs) on two serines in an SXS motif at their extreme C-termini. Phosphorylated R-SMADs form complexes with the common SMAD, SMAD4, which accumulate in the nucleus and directly regulate the transcription of target genes, leading to new programs of gene expression ([@bib65]). In the classic view of TGF-β family signaling, there are two branches, characterized by distinct combinations of type II and type I receptors, and the recruitment of specific R-SMADs to particular type I receptors ([@bib70]; [@bib65]). One branch is activated by TGF-β, Activins and NODAL and is mediated via the type I receptors TGFBR1, ACVR1B and ACVR1C (also known as ALK5, ALK4 and ALK7 respectively), which phosphorylate SMAD2 and 3. The other is activated by BMPs and GDFs and is mediated via ACVRL1, ACVR1, BMPR1A and BMPR1B (also known as ALK1, ALK2, ALK3 and ALK6 respectively), which phosphorylate SMAD1, 5 and 9 ([@bib46]).

In general, while this pairing between type I receptors and R-SMADs broadly fits the assignment of specific ligands to the different branches of TGF-β family signaling, it is an oversimplification. For example, ACVR1 is now described as a BMP receptor, but early work indicated that it could bind Activin and TGF-β ([@bib40]; [@bib45]), and very recently it has been shown to signal downstream of Activin in the context of the disease, fibrodysplasia ossificans progressiva ([@bib20]; [@bib22]). Furthermore, ACVRL1, a type I receptor that recognizes BMP9 and 10, also transduces TGF-β signals in endothelial cells ([@bib56]) by phosphorylating SMAD1/5 in parallel with the canonical TGF-β-induced phosphorylation of SMAD2/3 ([@bib17]; [@bib16]). This SMAD1/5 arm of TGF-β signaling has also been shown to occur in a wide range of other cell types, including epithelial cells, fibroblasts and cancer cell lines, which do not express ACVRL1 ([@bib37]; [@bib9]; [@bib36]; [@bib74]).

Important questions concerning this noncanonical TGF-β-induced SMAD1/5 phosphorylation remain unanswered. First, the mechanism by which TGF-β induces SMAD1/5 phosphorylation, in particular, the type I receptors involved, is not known. Some studies have concluded that the canonical TGF-β receptors TGFBR1 and TGFBR2 are sufficient for phosphorylation of both SMAD2/3 and SMAD1/5 ([@bib36]; [@bib74]). In contrast, others demonstrated that one of the classic BMP type I receptors (ACVR1 or BMPR1A), or in endothelial cells, ACVRL1, is additionally required ([@bib9]; [@bib17]; [@bib16]). The second crucial issue concerns the biological relevance of TGF-β-induced SMAD1/5 signaling. Nothing is known about the transcriptional program activated by this arm of TGF-β signaling, or indeed, the specific SMAD complexes involved. It is also not known to what extent this pathway is required for the physiological responses to TGF-β.

Here, we dissect the SMAD1/5 arm of TGF-β signaling and define the underlying mechanism and its biological function. We show that TGF-β-induced SMAD1/5 phosphorylation requires both TGFBR1 and ACVR1 and using biosensors, and an optogenetic approach, we establish a new paradigm for TGF-β receptor activation. We have mapped the binding sites on chromatin of nuclear phosphorylated SMAD1/5 (pSMAD1/5) genome-wide, which led us to define the target genes regulated by this arm of TGF-β signaling. We go on to show that this arm of signaling is required for TGF-β-induced EMT. Our data reveal that the full transcriptional programme activated in response to TGF-β requires integrated combinatorial signaling via both the SMAD2/3 and SMAD1/5 pathways.

Results {#s2}
=======

The kinetics of TGF-β-mediated SMAD1/5 phosphorylation {#s2-1}
------------------------------------------------------

To begin to dissect which receptors are required for TGF-β-induced SMAD1/5 phosphorylation, we compared the kinetics of SMAD1/5 and SMAD2 phosphorylation in response to TGF-β. Using the human breast cancer cell line MDA-MB-231 and the mouse mammary epithelial cell line NMuMG as model systems, we found that TGF-β induced only transient phosphorylation of SMAD1/5 that peaked at 1 hr and then returned to baseline ([Figure 1A](#fig1){ref-type="fig"}). This was in contrast to a more sustained TGF-β-induced SMAD2 phosphorylation, or SMAD1/5 phosphorylation in response to BMP4. However, transient SMAD1/5 phosphorylation is not a defining characteristic of this arm of TGF-β signaling, as another human breast cancer line, BT-549, exhibited sustained SMAD1/5 phosphorylation that is still readily detectable 8 hr after TGF-β stimulation ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Furthermore, when BT-549 cells were grown as non-adherent spheres, TGF-β-induced SMAD1/5 phosphorylation did not attenuate at all in the first 8 hr of signaling ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Thus, the kinetics of TGF-β-induced SMAD1/5 phosphorylation are cell-type-specific and dependent on the culture conditions and are independent of the kinetics of TGF-β-induced SMAD2/3 phosphorylation, suggesting a distinct receptor complex may be involved.

![Characterization of SMAD1/5 phosphorylation by TGF-β.\
(**A**) MDA-MB-231 and NMuMG cells were treated with TGF-β or BMP4 for the times indicated. (**B**) MDA-MB-231 cells were treated with TGF-β for the times shown either alone or after 5 min pre-treatment with cyclohexamide (CHX) or actinomycin D (Act D). (**C**) MDA-MB-231 cells were treated with TGF-β for 1 or 8 hr, and after 8 hr, cells were re-stimulated with TGF-β or BMP4 for 1 hr as shown in the scheme. For comparison, cells were stimulated for 1 hr with BMP4. (**D**) MDA-MB-231 cells were induced or not with TGF-β or BMP4 in the presence of either 0.25 µM or 10 µM SB-431542 (SB) or 1 µM LDN-193189 (LDN) or a combination of 0.25 µM or 10 µM SB-431542 and 1 µM LDN-193189. In all panels, western blots are shown probed with the antibodies indicated. B, BMP4, Un, unstimulated. In B, SERPINE1, whose expression is induced by TGF-β, provides a control for the efficacy of the CHX and Act D.](elife-31756-fig1){#fig1}

To address whether new protein synthesis was required for the transient nature of TGF-β-induced SMAD1/5 phosphorylation, cells were induced with TGF-β in the presence of either a translation inhibitor, cycloheximide or a transcription inhibitor, actinomycin D. Inhibition of translation was uninformative because it also led to a very rapid loss of TGFBR2 and TGFBR1, due to their short half-lives ([@bib69]). Use of actinomycin D, however, circumvented this problem, as *TGFBR2* and *TGFBR1* mRNAs are relatively stable ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) and their translation was unimpeded. In these conditions, SMAD1/5 phosphorylation was sustained ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Thus, the rapid loss of pSMAD1/5 at later time points after TGF-β stimulation requires new transcription, suggesting that it is mediated by a component whose expression is induced by TGF-β.

Acute TGF-β stimulation results in the rapid internalization of the receptors, which is sufficient to deplete almost all of the type II receptor TGFBR2 from the cell surface ([@bib69]). As a result, cells are refractory to further acute TGF-β stimulation, read out by SMAD2 phosphorylation ([@bib69]). Cells in this refractory state were also unable to induce SMAD1/5 phosphorylation in response to TGF-β, although they remained responsive to BMP4 ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). This suggested that TGFBR2 is required for TGF-β-induced SMAD1/5 activation.

TGF-β-induced SMAD1/5 phosphorylation requires the kinase activity of two different type I receptors {#s2-2}
----------------------------------------------------------------------------------------------------

The distinct kinetics of TGF-β-induced SMAD1/5 phosphorylation compared with SMAD2/3 phosphorylation suggested that different receptor complexes are likely involved. To explore this further, we used combinations of well-characterized small molecule inhibitors of the type I receptor kinases in MDA-MB-231 cells. SB-431542, a selective TGFBR1/ACVR1B/ACVR1C inhibitor ([@bib26]), completely inhibited the phosphorylation of both SMAD1/5 and SMAD2 in response to TGF-β when used at 10 µM ([Figure 1D](#fig1){ref-type="fig"}), indicating that the kinase activity of TGFBR1 is essential for TGF-β-induced SMAD1/5 phosphorylation. Interestingly, a 40-fold lower dose also substantially inhibited SMAD1/5 phosphorylation, whilst having less effect on SMAD2 phosphorylation ([Figure 1D](#fig1){ref-type="fig"}). TGF-β-induced SMAD1/5 phosphorylation was also partially inhibited by the BMP type I receptor inhibitor LDN-193189 ([@bib7]) ([Figure 1D](#fig1){ref-type="fig"}), establishing a requirement for a member of this class of type I receptors. Strikingly, the combination of the low-dose SB-431542 and LDN-193189 completely inhibited TGF-β-dependent SMAD1/5 phosphorylation, without affecting phosphorylation of SMAD2 ([Figure 1D](#fig1){ref-type="fig"}). Analogous results were obtained in NMuMG cells ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}).

We conclude that the kinase activity of both classes of type I receptor is required for maximal SMAD1/5 phosphorylation downstream of TGF-β. Taking these results together with the receptor expression profiles of these cells and receptor knockdown experiments ([@bib9]), we deduce that the receptors involved are TGFBR1, a canonical BMP type I receptor (ACVR1 and/or BMPR1A) and TGFBR2.

SMAD1 is primarily phosphorylated by ACVR1 {#s2-3}
------------------------------------------

We next used an in vitro approach to explore why TGF-β-induced phosphorylation of SMAD1 requires two different type I receptors. We focused on ACVR1 as a representative of the BMP type I receptor class, as it is the most homologous to ACVRL1 that responds to TGF-β in endothelial cells ([@bib5]). Moreover, in some cell types, knockdown of ACVR1 was sufficient to block TGF-β-induced pSMAD1/5 ([@bib9]).

SMAD1 is known to be a poor substrate for TGFBR1 in vivo ([@bib30]; [@bib23]). We demonstrated that SMAD1 is also a poor substrate for TGFBR1 in vitro, although it is efficiently phosphorylated by both ACVR1 and BMPR1A as expected ([Figure 1---figure supplement 2A,B](#fig1s2){ref-type="fig"}). As a control, we showed that TGFBR1 could potently phosphorylate SMAD2, and surprisingly, ACVR1 was also able to phosphorylate SMAD2 ([Figure 1---figure supplement 2A,B](#fig1s2){ref-type="fig"}).

Given that SMAD1 is a poor substrate for TGFBR1, it is intriguing that the kinase activity of TGFBR1 is essential for TGF-β-induced SMAD1 phosphorylation. We hypothesized that TGFBR1 might catalyze a priming phosphorylation on SMAD1, which then serves as a substrate for ACVR1, or *vice versa*. To address this, we mapped the sites phosphorylated by ACVR1 on full length SMAD1. We identified three species of C-terminal SMAD1 phosphorylation by ACVR1 -- a dually phosphorylated S\[pS\]V\[pS\] and the singly phosphorylated \[pS\]SVS and S\[pS\]VS ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). From this it was clear that ACVR1 could phosphorylate both serines in the critical SVS motif and we deduced that the order of phosphorylation is the penultimate serine of the motif, followed by the terminal one. Moreover, if the preceding serine was phosphorylated, it prevented the phosphorylation of the other sites.

Taking all these results together, we conclude that in response to TGF-β, the receptor kinase that phosphorylates SMAD1 is ACVR1 and not TGFBR1, and it does so on both serines in the SVS motif in a defined order.

ACVR1 is activated by TGFBR1 in vitro and in vivo {#s2-4}
-------------------------------------------------

The absence of a role for the TGFBR1 kinase activity in phosphorylating SMAD1 left open the question of why it is required in vivo for TGF-β-induced SMAD1/5 phosphorylation. We postulated that it might be necessary for ACVR1 activation, and therefore investigated whether TGFBR1 could directly phosphorylate ACVR1. Both TGFBR1 and ACVR1 exhibit significant autophosphorylation activity in vitro, which was inhibited by SB-505124 (another more potent TGFBR1 inhibitor; [@bib8]) and LDN-193189, respectively ([Figure 2A](#fig2){ref-type="fig"}). Crucially, when TGFBR1 and ACVR1 were co-incubated, ACVR1 was phosphorylated, even in the presence of LDN-193189, indicating that ACVR1 *is* a substrate of TGFBR1 ([Figure 2A](#fig2){ref-type="fig"}).

![ACVR1 is activated by TGFBR1 in vitro and in vivo.\
(**A**) The kinase domains of TGFBR1 and ACVR1 were analyzed alone or together in an in vitro kinase reaction. SB-505124 and LDN-193189 were included as shown to inhibit the activity of TGFBR1 and ACVR1, respectively. The autoradiograph is shown in the top panel, with the Coomassie-stained gel below as a loading control. (**B**) Schematic to show the domain organization of the Opto receptors. In Opto-TGFBR1\* and Opto-ACVR1, the kinase domains of TGFBR1 and ACVR1 are fused to the light-sensitive LOV domain. At the N-terminus there is a myristylation domain (indicated by the red zig zag). At the C-terminus there is an HA tag. The kinase domain of TGFBR1 contains the activating mutation T204D. These Opto receptors dimerize in the presence of blue light. (**C**) NIH-3T3 cells were untransfected or transfected with FLAG-SMAD1 together with either Opto-TGFBR1\*, Opto-ACVR1 or both receptors together. Post-transfection, cells were either kept in the dark or exposed to blue light for 1 hr. Whole cell extracts were western blotted using antibodies against pSMAD1/5 (which detects endogenous and FLAG-tagged pSMAD1/5), SMAD1 (which detects endogenous and FLAG-SMAD1), HA (to detect the Opto receptors) and Tubulin as a loading control. (**D**) NIH-3T3 cells were untransfected or transfected with FLAG-SMAD1 together with either Opto-TGFBR1\*, Opto-ACVR1 or both receptors together. Post-transfection, cells were either kept in the dark or exposed to blue light for 1 hr. The inductions were performed in the absence or presence of 0.5 µM LDN-193189 or 50 µM SB-505124 as indicated. Whole cell extracts were blotted as in (**C**). (**E**) The experimental set up was as in (**D**) except that GFP-SMAD3 was used instead of FLAG-SMAD1 to assess the activity of Opto-TGFBR1\*. (**F**) As in (**C**), except that an ACVR1 mutant in which all the threonines and serines of the GS domain were mutated to valine or alanine respectively, was also assayed. (**G**) As in (**F**), except that GFP-SMAD3 was used instead of FLAG-SMAD1. Note that in all cases the 1 hr induction with blue light led to reduced levels of the transfected receptors and substrates.](elife-31756-fig2){#fig2}

To determine whether TGFBR1 could activate ACVR1 in vivo, we used an optogenetic approach. To this end, we fused the light-oxygen-voltage (LOV) domain of aureochrome1 from *Vaucheria frigida*, which dimerizes upon blue light stimulation ([@bib64]), to the C-terminal ends of the intracellular domains of a constitutively-activated TGFBR1 (mutation T204D) ([@bib72]) and of wild-type ACVR1, along with an N-terminal myristoylation motif to anchor them to the plasma membrane ([Figure 2B](#fig2){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). We refer to these constructs as Opto-TGFBR1\* and Opto-ACVR1, respectively. We tested their ability, alone or in combination, to induce phosphorylation of SMAD1/5 in NIH-3T3 cells co-transfected with FLAG-SMAD1 to increase the range of the assay. Transfection of the Opto-ACVR1 alone resulted in no phosphorylation of co-transfected FLAG-SMAD1, either in the absence or presence of blue light. However, when Opto-ACVR1 and Opto-TGFBR1\* were co-transfected, a robust light-inducible phosphorylation of FLAG-SMAD1 was observed ([Figure 2C](#fig2){ref-type="fig"}). Importantly, this was inhibited by both SB-505124 and LDN-193189, confirming the involvement of both receptors ([Figure 2D](#fig2){ref-type="fig"}). This directly demonstrates that TGFBR1 can activate ACVR1 in vivo. As a control, we showed that Opto-TGFBR1\* phosphorylated co-expressed GFP-SMAD3 in the presence of light, which was inhibited by SB-505124, but to a much lesser extent by LDN-193189 ([Figure 2E](#fig2){ref-type="fig"}). As a further control to ensure that the activation of ACVR1 by TGFBR1 required the kinase activity of the latter, we made a kinase-dead version of Opto-TGFBR1. This construct was unable to induce the activity of ACVR1 in a light-inducible manner and was also unable to induce phosphorylation of GFP-SMAD3 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

To confirm that the light-inducible phosphorylation of FLAG-SMAD1 observed with the combination of Opto-ACVR1 and Opto-TGFBR1\* genuinely resulted from activation of Opto-ACVR1 by Opto-TGFBR1\*, we generated a mutant version of Opto-ACVR1, in which the serines and threonines of the GS domain were mutated to alanine and valine, respectively. Since phosphorylation of these serines and threonines is required for type I receptor activation, we would expect this mutant to be uninducible ([@bib72]). Indeed, we found that light-inducible phosphorylation of FLAG-SMAD1 was inhibited when this GS domain mutant of Opto-ACVR1 was used instead of the wild-type Opto-ACVR1 ([Figure 2F,G](#fig2){ref-type="fig"}).

We therefore conclude that the requirement of the kinase activity of both TGFBR1 and ACVR1 for TGF-β-induced phosphorylation of SMAD1/5 reflects a requirement for activation of ACVR1 by TGFBR1 through phosphorylation of the ACVR1 GS domain.

TGF-β leads to clustering of ACVR1 and TGFBR1 {#s2-5}
---------------------------------------------

Having shown that both type I receptors are required, we next tested whether they were components of the same tetrameric receptor complex, or whether they resided in separate receptor complexes that clustered at the cell membrane in response to ligand stimulation (compare model I and model II, [Figure 3A](#fig3){ref-type="fig"}). To distinguish between these possibilities, we used previously published recombinant versions of TGF-β3, designated WW and WD ([@bib25]). TGF-β3^WW^, the wild-type TGF-β3 dimer, is composed of two identical monomeric TGF-β3 subunits, whereas TGF-β3^WD^ contains one wild-type subunit of TGF-β3 and one mutated subunit that cannot bind to either TGFBR2 or TGFBR1 ([@bib25]). Thus, while the TGF-β3^WW^ ligand engages two type II:type I pairs in the tetrameric complex, the TGF-β3^WD^ ligand can only engage one pair. In addition, TGF-β3^WW^ does not bind ACVR1, and by inference, neither does TGF-β3^WD^ (data not shown). It was previously demonstrated that TGF-β3^WD^ binding to a single type II:type I receptor pair is sufficient to induce phosphorylation of SMAD3 ([@bib25]). We therefore reasoned that if model I was correct then only TGF-β3^WW^ would induce phosphorylation of SMAD1/5, as the heterotetrameric complex would not be able to be assembled by TGF-β3^WD^. If model II was correct, however, then both TGF-β3^WW^ and TGF-β3^WD^ would be competent to induce pSMAD1/5. Treatment of MDA-MB-231 or NMuMG cells with either TGF-β3^WW^ or TGF-β3^WD^ led to a dose-dependent increase in both SMAD1 and SMAD2 phosphorylation ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Thus, TGF-β stimulation is unlikely to lead to formation of a heterotetrameric complex comprising TGFBR2/TGFBR1/ACVR1, but instead, leads to the formation of a higher order receptor cluster at the cell surface that includes TGFBR2/TGFBR1 complexes and ACVR1.

![TGFBR1 and ACVR1 are present in distinct receptor complexes upon TGF-β stimulation.\
(**A**) Alternative models of receptor clustering mediated by TGF-β3 derivatives capable of interacting with two pairs (TGF-β3^WW^) or one pair (TGF-β3^WD^) of type II:type I receptors. If an obligate heterotetramer of two type I:type II pairs is required for SMAD1/5 phosphorylation (Model I), then only TGF-β3^WW^ would lead to SMAD1/5 phosphorylation. If TGF-β induces higher order receptor clustering at the cell surface (Model II), then both TGF-β3^WW^ and TGF-β3^WD^ would lead to SMAD1/5 phosphorylation. (**B**) MDA-MB-231 cells were treated with different concentrations of TGF-β3^WW^ or TGF-β3^WD^ for 1 hr as indicated. As a control, cells were either untreated (Un) or treated with TGF-β1 (T) or BMP4 (B) for 1 hr. Whole cell lysates were western blotted using the antibodies shown.](elife-31756-fig3){#fig3}

TGF-β induces ACVR1 activation in vivo in a TGFBR1-dependent manner {#s2-6}
-------------------------------------------------------------------

To obtain direct evidence that TGF-β activates ACVR1, we generated an ACVR1 biosensor that fluoresces when activated. In this construct, ACVR1 is fused to the conformation-sensitive circularly permutated yellow fluorescent protein (cpYFP) core of the InversePericam Ca^2+^ sensor and FKBP1A (formerly FKBP12) to make ACVR1-InversePericam-FKBP1A (ACVR1-IPF) ([@bib44]). When the receptor is inactive, the FKBP1A moiety binds to the GS domain of the receptor, which suppresses cpYFP fluorescence. Upon ligand induction, phosphorylation of the GS domain releases FKBP1A, allowing the cpYFP to adopt a fluorescent conformation ([@bib44]). We first showed that ACVR1-IPF is functional in that it is able to induce phosphorylation of SMAD1/5 when overexpressed ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). We then stably expressed this biosensor in a number of cell lines ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). In the polarized epithelial cell line, MDCKII and in NIH-3T3 fibroblasts, ACVR1-IPF is readily detectable at the cell membrane, as well as in internal structures, and had no adverse effect on the inducibility of these cells in response to TGF-β or BMP4 ([Figure 4---figure supplement 1B--D](#fig4s1){ref-type="fig"}). As a control, we showed that ACVR1-IPF was activated in response to FK506 which binds FKBP1A and releases it from the GS domain of ACVR1 ([@bib71]) ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Treatment of the MDCKII ACVR1-IPF cells with TGF-β resulted in a significant increase in fluorescence that was inhibited by SB-431542 ([Figure 4A and B](#fig4){ref-type="fig"}; [Videos 1](#video1){ref-type="video"}--[3](#video3){ref-type="video"}). Furthermore, using flow cytometry for a more quantitative approach we demonstrated that the TGF-β-induced increase in fluorescence was blocked by both SB-431542 and a TGF-β neutralizing antibody and was independent of BMP signaling, as it was unaffected by the BMP antagonist Noggin ([Figure 4C](#fig4){ref-type="fig"}). Similarly, TGF-β also activated ACVR1 in NIH-3T3 ACVR1-IPF cells in a TGFBR1-dependent manner ([Figure 4---figure supplement 1F,G](#fig4s1){ref-type="fig"}; [Videos 4](#video4){ref-type="video"}--[6](#video6){ref-type="video"}).

![ACVR1 is activated by TGF-β in a TGFBR1-dependent manner.\
(**A and B**) MDCKII ACVR1-IPF cells were imaged at 15 min intervals for 60 min before the addition (arrow) of either media alone or media containing TGF-β ± 10 µM SB-431542 for a further 150 min. The panels in (**A**) are stills of the maximum intensity projections at the times shown. The quantifications are shown in (**B**). The fluorescence at the 60 min time point was taken as the reference that was subtracted from all other time points. Data presented are the mean ± SD of three independent fields. Statistical significance is shown for the indicated pairs of conditions at the 210 min time point. (**C**) Fluorescence in MDCKII ACVR1-IPF cells assayed by flow cytometry 24 hr after treatment. Each panel shows an overlay of the indicated treatment conditions. The black line indicates the median of the untreated (Un) sample. Quantifications are shown on the right. For each group, the percentage of cells greater than the median fluorescence intensity of the untreated sample was quantified. Data are the mean ± SEM of three independent experiments. SB, SB-431542 at 10 µM; Ab, antibody; Nog, noggin; C, control antibody; B, blocking antibody.\
10.7554/eLife.31756.016Figure 4---source data 1.Source data for ACVR1-IPF fluorescence (panel B).\
10.7554/eLife.31756.017Figure 4---source data 2.Source data for ACVR1-IPF fluorescence by flow cytometry (panel C).](elife-31756-fig4){#fig4}

###### Fluorescence in MDCKII ACVR1-IPF cells treated with media alone.

MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of media alone followed by imaging for a further 2.5 hr. Very little increase in fluorescence was observed over the time course.

10.7554/eLife.31756.018

###### Fluorescence in MDCKII ACVR1-IPF cells treated with TGF-β.

MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of 2 ng/ml TGF-β followed by imaging for a further 2.5 hr. Significant increase in fluorescence was observed over the time course with intracellular puncta of fluorescence becoming more evident over time.

10.7554/eLife.31756.019

###### Fluorescence in MDCKII ACVR1-IPF cells treated with TGF-β and SB-431542.

MDCKII ACVR1-IPF cells were imaged for 1 hr prior to the addition of 2 ng/ml TGF-β + 10 μM SB-431542 to the cells followed by imaging for a further 2.5 hr. Very little increase in fluorescence was observed over the time course.

10.7554/eLife.31756.020

###### Fluorescence in NIH-3T3 ACVR1-IPF cells treated with media alone.

NIH-3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of media alone. A modest and gradual increase in fluorescence was observed over the time course.

10.7554/eLife.31756.021

###### Fluorescence in NIH-3T3 ACVR1-IPF cells treated with TGF-β.

NIH-3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of 2 ng/ml TGF-β. A significant increase in fluorescence was observed over the time course with fluorescence becoming more evident on membrane projections and intracellular vesicles over time.

10.7554/eLife.31756.022

###### Fluorescence in NIH-3T3 ACVR1-IPF cells treated with TGF-β and SB-431542.

NIH-3T3 ACVR1-IPF cells were imaged for 3.5 hr after the addition of 2 ng/ml TGF-β + 10 μM SB-431542. A modest and gradual increase in fluorescence was observed over the time course.

10.7554/eLife.31756.023

Mapping the binding sites on chromatin for TGF-β-induced pSMAD1/5 reveals that *ID* genes are major transcriptional targets of this pathway {#s2-7}
-------------------------------------------------------------------------------------------------------------------------------------------

Although the existence of TGF-β-induced pSMAD1/5 has been known for some time, its transcriptional role has never been addressed. Earlier experiments had suggested that TGF-β-induced pSMAD1/5 could only be found in complex with pSMAD2/3 ([@bib9]), but using optimized immunoprecipitation conditions it was clear that TGF-β-induced pSMAD1/5 can also be part of pSMAD1/5--SMAD4 complexes ([Figure 5A](#fig5){ref-type="fig"}). We therefore used chromatin immunoprecipitation sequencing (ChIP-seq) for pSMAD1/5 to explore where in the genome pSMAD1/5 binds in response to TGF-β. We also wanted to determine which SMAD complexes were primarily responsible for regulating transcription in addition to the canonical pSMAD2/3--SMAD4 complexes ([Figure 5A](#fig5){ref-type="fig"}).

![pSMAD1/5 is recruited to chromatin in response to TGF-β and is most highly enriched at GGCGCC motifs.\
(**A**) MDA-MB-231 cells were either untreated (-) or treated with TGF-β (+) for 1 hr. Whole cell extracts were immunoprecipitated (IP) with the antibodies (Ab) indicated or beads alone (Be). The IPs were western blotted using the antibodies shown. Inputs are shown on the left. (**B**) IGV browser displays over the *ID1*, *ID3* and *JUNB* loci after ChIP-Seq of MDA-MB-231 untreated (Un) and TGF-β-treated samples. IPs were performed with antibodies against pSMAD1/5 (pS1/5), SMAD3 (S3) or with beads alone as a negative control. Inputs are also shown. Red lines indicate regions validated in (**C**). U; upstream peak; D1, downstream peak 1. (**C**) Genomic regions were validated by ChIP-qPCR after treatment of MDA-MB-231 cells with TGF-β (T) or BMP4 (B) for the times shown. IPs were as in (**B**). A representative experiment of two performed in triplicate is shown with means ± SD. (**D**) The most enriched motif obtained from a MEME-ChIP analysis of the top 100 pSMAD1/5 peaks. (**E**) Proportion of variants of the GGCGCC motif identified in the top 100 pSMAD1/5 peaks.\
10.7554/eLife.31756.033Figure 5---source data 1.ChIP-seq datasets.\
10.7554/eLife.31756.034Figure 5---source data 2.ChIP-PCR data for graphs in panel C.](elife-31756-fig5){#fig5}

ChIP-seq in MDA-MB-231 cells for pSMAD1/5 and SMAD3 (as a control) resulted in 2378 pSMAD1/5 peaks and 2440 SMAD3 peaks identified in response to TGF-β after filtering ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, sheet 1). The majority of the pSMAD1/5 peaks (2287) were also bound by SMAD3. To identify binding sites preferentially bound by pSMAD1/5 versus SMAD3 we calculated the ratio of the number of tags in the pSMAD1/5 peaks versus the SMAD3 peaks, and focused on the 100 peaks with the highest pSMAD1/5:SMAD3 tag ratio ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, sheet 2). Interrogating the nearest genes to these peaks we found a significant enrichment of both TGF-β and BMP target genes ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, sheets 2 and 3). Strikingly, 8 of the top 10 peaks flanked known BMP target genes (*ID1, ID3, ID4, ATOH8, BIRC3*) ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, sheet 2) ([@bib18]). In contrast, classical TGF-β target genes like *JUNB, BHLHE40, PMEPA1, SERPINE1* ([@bib33]) were not in this top 100 list, but were amongst those with the highest enrichment for SMAD3 ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, sheet 1). Using ChIP-qPCR, we validated these different binding patterns ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). For pSMAD1/5, the binding in response to TGF-β was transient, peaking at 1 hr and thereafter decreasing, whilst SMAD3 binding at *JUNB* and *PMEPA1* was sustained. A subset of the peaks were also validated in BT-549 cells ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

We performed motif enrichment analyses on the top 50 and 100 peaks with the highest pSMAD1/5:SMAD3 tag ratio. In both cases, a SMAD1/5 binding motif GGCGCC was found ([Figure 5D and E](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}) ([@bib14]). In addition, in the top 50 peaks the composite SMAD1/5--SMAD4 site was clearly identified (GGCGCC(N~5~)GTCT) ([@bib14]; [@bib50]) ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), with a slightly more degenerate version being present in the top 100 peaks ([Figure 5D](#fig5){ref-type="fig"}). This strongly suggests that TGF-β-induced SMAD1/5--SMAD4 complexes are responsible for regulating the genes with the highest enrichment of pSMAD1/5.

The enrichment of pSMAD1/5 on the *ID* genes in response to TGF-β suggests that they are *bona fide* target genes of this arm of TGF-β signaling. We confirmed this using siRNAs to deplete specific SMADs. TGF-β induction of *ID1* and *ID3* in MDA-MB-231 cells depended on SMAD1/5 and SMAD4, but not SMAD3 ([Figure 5---figure supplement 2A and B](#fig5s2){ref-type="fig"}). In contrast, the induction of *JUNB* required SMAD3 and SMAD4, but was independent of SMAD1/5 ([Figure 5---figure supplement 2A and B](#fig5s2){ref-type="fig"}). We further corroborated these observations using the drug dosing strategy that selectively inhibits SMAD1/5 phosphorylation in response to TGF-β ([Figure 1D](#fig1){ref-type="fig"}). The combination of low-dose SB-431542 and LDN-193189 greatly decreased *ID* gene induction without impacting on the induction of *JUNB* in both MDA-MB-231 and NMuMG cells ([Figure 5---figure supplement 2C and D](#fig5s2){ref-type="fig"}). The induction of target gene expression was also examined after treatment of cells with TGF-β3^WW^ or TGF-β3^WD^. As expected both TGF-β ligands induced the expression of the *ID*s and *JUNB* ([Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}).

The results in this section reveal that pSMAD1/5--SMAD4 complexes formed in response to TGF-β are responsible for regulating the genes with the highest enrichment of pSMAD1/5, and that the *ID*s are major early downstream targets.

The SMAD1/5 arm of TGF-β signaling is required for TGF-β-induced EMT {#s2-8}
--------------------------------------------------------------------

The ID proteins have been implicated in many processes involved in oncogenesis ([@bib31]), and importantly, ID1 was shown to be upregulated by TGF-β in tumor cells isolated from pathological pleural fluids from patients with ER− and ER+ metastatic breast cancer, and also in patient-derived glioblastomas ([@bib1]; [@bib55]). Since we have now shown that the pSMAD1/5 arm of TGF-β signaling is responsible for TGF-β-induced *ID1* induction, this prompted us to explore further the biological relevance of the pSMAD1/5 arm of TGF-β signaling in oncogenic processes, and to gain a comprehensive view on the relative contribution of this arm of signaling to longer term TGF-β responses. We decided to focus on the process of EMT, as this is a key step in tumorigenesis that confers a migratory phenotype, acquisition of stem cell properties and resistance to chemotherapeutic agents ([@bib77]). For these studies, we primarily used the NMuMG cell model, as we have shown above that these cells show a robust phosphorylation of SMAD1/5 in response to TGF-β and are well known to undergo a TGF-β-induced EMT within 48 hr ([@bib58]).

CRISPR/Cas9 was used to generate clones of NMuMG cells deleted for SMAD1 and SMAD5 ([Figure 6A](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1A--C](#fig6s1){ref-type="fig"}). We compared the TGF-β-induced transcriptome at 48 hr of the parental clone with one deleted for SMAD1/5 using RNA-sequencing (RNA-seq). Of the 5798 genes that are significantly up- or down-regulated by TGF-β in this time frame we found that approximately a quarter (1398) were dependent on the SMAD1/5 branch of signaling (see Materials and methods for the cut-offs used) ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, sheets 1 and 2). This demonstrates that this arm of TGF-β signaling plays a crucial role in long term downstream transcription responses. To corroborate the RNA-seq results, we validated a subset of them by qPCR, measuring levels of mRNA over time in response to TGF-β ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

![SMAD1/5 is required for TGF-β-induced EMT.\
(**A**) The parental NMuMG clone and the ΔSMAD1/5 clone 1 were treated with TGF-β or BMP4 for the times shown. Whole cell extracts were immunoblotted with the antibodies indicated. (**B**) Parental NMuMG clone and the ΔSMAD1/5 clone 1 cells were left untreated or treated with TGF-β for 48 hr and imaged after indirect immunofluorescence (IF) using antibodies against TJP1 and CDH1. A merge of the two with DAPI in blue is also shown. (**C**) NMuMG cells were left untreated (Un) or treated with TGF-β alone or in combination with 1 µM LDN-193189 (LDN) ± 0.125 µM SB-431542 (SB) for 48 hr. Panels show cells imaged under either phase contrast (left panels) or by indirect immunofluorescence (IF) using antibodies against TJP1 and CDH1. A merge of the two with DAPI in blue is also shown. (**D**) NMuMG cells were left untreated or treated with TGF-β alone or in combination with either 1 µM LDN-193189 ± 0.125 µM SB-431542 for 48 hr. Whole cell lysates were immunoblotted with the indicated antibodies. (**E**) EpRas cells were left untreated (Un) or treated with TGF-β alone or in combination with 1 µM LDN-193189 (LDN) ± 0.125 µM SB-431542 (SB) for 9 days, then imaged after indirect immunofluorescence (IF) using antibodies against TJP1 and CDH1 or a merge of the two with DAPI in blue. (**F**) EpRas cells were left untreated or treated with TGF-β for 1 hr alone or with combinations of 1 µM LDN-193189, 0.125 µM SB-431542 or 10 µM SB-431542 as indicated. Whole cell lysates were immunoblotted with the indicated antibodies. In (**B**), (**C**) and (**E**) the indirect IF images are maximum intensity projections of a z-stack in each channel.\
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Gene set enrichment analysis revealed that the TGF-β target genes that depend on this arm of signaling were involved in processes such as regulation of the cytoskeleton, focal adhesions, adherens and tight junctions, as well as EMT ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, sheet 3). We therefore next investigated whether TGF-β-induced EMT required SMAD1/5 signaling. Using delocalization of the adherens junction marker CDH1 (also called E-Cadherin) together with loss of the tight junction marker TJP1 (also called ZO-1) as a measure of EMT, we could readily demonstrate that signaling through SMAD1/5 was crucial for this process in two separate ΔSMAD1/5 clones ([Figure 6B](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). In addition, we observed that two mesenchymal markers, *Acta2* (also called smooth muscle actin) and *Fn1* were more weakly induced in the ΔSMAD1/5 clone compared with the wild-type ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). We also used an siRNA knockdown approach, and showed that EMT was dependent on SMAD1/5, SMAD4 and SMAD3, but independent of SMAD2 ([Figure 6---figure supplement 3A and B](#fig6s3){ref-type="fig"}). Furthermore, treatment of the cells with the BMP type I receptor inhibitor, LDN-193189 also inhibited EMT either alone or when combined with low-dose SB-431542 which we have shown is sufficient to inhibit TGF-β-induced SMAD1/5 signaling, but not signaling through SMAD2/3 ([Figure 6C and D](#fig6){ref-type="fig"}; [Figure 6---figure supplement 3C](#fig6s3){ref-type="fig"}). Moreover, DMH1, another BMP type I receptor inhibitor, had a similar effect ([Figure 6---figure supplement 3C and D](#fig6s3){ref-type="fig"}). Finally, to confirm that the dependence of TGF-β-induced EMT on SMAD1/5 signaling was not unique to NMuMG cells, we used another mouse mammary cell line, EpRas that also undergoes a TGF-β-induced EMT ([@bib10]; [@bib19]). SMAD1/5 signaling in this line was also essential for EMT ([Figure 6E and F](#fig6){ref-type="fig"}). Thus, we conclude that TGF-β-induced EMT requires the SMAD1/5 arm of the signaling pathway, as well as the canonical pathway through SMAD3.

Taking our ChIP-seq and RNA-seq analyses together, we found that the *ID* genes are major early transcriptional targets of the SMAD1/5 arm of the TGF-β pathway. Of these, ID1 was the prominent family member up-regulated by TGF-β in NMuMGs ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). We hypothesized that the dependency on the SMAD1/5 arm of the TGF-β pathway could reflect a requirement of ID1 for EMT. We tested this by knocking down *Id1* with siRNAs, both as a pool and as individual siRNAs and found that cells depleted of ID1 were indeed unable to undergo TGF-β-induced EMT ([Figure 7A and B](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1B and C](#fig7s1){ref-type="fig"}). Thus, we conclude that TGF-β-induced up-regulation of ID1 is essential for EMT.

![TGF-β-induced ID1 via pSMAD1/5 is required for EMT.\
(**A**) NMuMG cells were transfected with siRNAs against *ID1* or NT control, then left untreated or treated with TGF-β for 24 hr. Cells were imaged after indirect IF with antibodies against TJP1 and CDH1 or a merge of the two with DAPI in blue. All indirect IF images are maximum intensity projections of a z-stack in each channel. (**B**) Western blots to show knockdown efficiency of the *ID1* siRNA. NMuMG cells were treated with TGF-β (T) or BMP4 (B) for 1 hr. (**C**) The model shows combinatorial signaling by TGF-β utilizing complexes containing two different type I receptors. Type II receptors are shown in blue, TGFBR1 in orange and ACVR1 in green as in [Figure 3A](#fig3){ref-type="fig"}. P denotes phosphorylation. S1/5, SMAD1/5; S2/3, SMAD2/3; S4, SMAD4. The question mark indicates that we do not yet know the function of the mixed R-SMAD complexes in the physiological responses. For discussion, see text.](elife-31756-fig7){#fig7}

Discussion {#s3}
==========

Combinatorial signaling downstream of TGF-β {#s3-1}
-------------------------------------------

Here, we have defined both the mechanism whereby TGF-β induces the phosphorylation of SMAD1/5, and its functional role. We have shown that two type I receptors are required, the canonical TGF-β receptor TGFBR1, and additionally, one of the classical BMP type I receptors, ACVR1. Using in vitro kinase assays, an optogenetic approach and an ACVR1 receptor fluorescent biosensor, we have uncovered a new mechanism for receptor activation whereby one type I receptor activates another. We show that in response to TGF-β, TGFBRI phosphorylates and activates ACVR1, which phosphorylates SMAD1/5. To address the functional significance of this arm of TGF-β signaling, we used genome-wide ChIP-seq and RNA-seq and show that approximately a quarter of the TGF-β-regulated transcriptome is dependent on SMAD1/5, with major early targets being the ID transcriptional regulators. Finally, we have also demonstrated that the SMAD1/5 pathway is essential for TGF-β-induced EMT, and this reflects a requirement for ID1.

Taking these results together with previous work ([@bib36]; [@bib9]), we propose a model of combinatorial signaling that is essential for the TGF-β cellular program ([Figure 7C](#fig7){ref-type="fig"}). In most cells tested the induction of pSMAD1/5 is more transient than the pSMAD2/3 induction ([@bib36]; [@bib9]). Thus, the initial transcriptional program is regulated by both SMAD pathways and is refined at later time points by the SMAD2/3 pathway. Therefore, the full TGF-β-induced transcriptional program requires combinatorial signaling via both SMAD pathways. With respect to the functional relevance of TGF-β-induced SMAD1/5 phosphorylation, we have now shown that complete EMT requires both SMAD pathways. TGF-β-induced anchorage-independent growth, migration and invasion have also been shown to require SMAD1/5 signaling, whilst TGF-β-induced growth arrest is only dependent on SMAD2/3 signaling ([@bib36]; [@bib9]) ([Figure 7C](#fig7){ref-type="fig"}).

Since we have now demonstrated that TGF-β induces the formation of SMAD1/5--SMAD4 complexes that regulate canonical BMP target genes, it is important to ask what discriminates TGF-β signaling from BMP signaling as it is well known that BMP and TGF-β functional responses are distinct ([@bib27]; [@bib48]). The answer lies in the combinatorial signaling, and likely also in the signaling dynamics. In contrast to TGF-β, BMP stimulation leads to a sustained phosphorylation of SMAD1/5 in the absence of SMAD2/3 activation ([@bib18]; [@bib9]). As a result, although the gene expression program downstream of BMP shares some common targets with that downstream of TGF-β at early time points, it will be completely distinct at later time points as a result of the sustained SMAD1/5 signaling and the absence of SMAD2/3-driven transcription ([Figure 7C](#fig7){ref-type="fig"}).

Receptor requirements for TGF-β-induced SMAD1/5 phosphorylation {#s3-2}
---------------------------------------------------------------

We have shown that two classes of type I receptors are necessary for TGF-β-induced SMAD1/5 phosphorylation, the canonical TGF-β receptor, TGFBR1 and one of the BMP type I receptors, of which we have focused on ACVR1. Our results demonstrate that the kinase activity of TGFBR1 is essential for activation of ACVR1, whereas the kinase activity of ACVR1 is necessary to phosphorylate SMAD1/5. Surprisingly, we found that inhibition of TGF-β-induced SMAD1/5 phosphorylation by LDN-193189, which inhibits the BMP type I receptors, is incomplete, even though the same LDN-193189 concentration is sufficient to inhibit BMP-induced SMAD1/5 phosphorylation. This same result was also previously seen when the BMP type I receptor inhibitor dorsomorphin was used ([@bib9]). A complete inhibition of TGF-β-induced pSMAD1/5 is achieved by combining LDN-193189 with a sub-optimal dose of SB-431542. This is likely explained by the fact that LDN-193189-inhibited ACVR1 is still able to efficiently recruit SMAD1/5, where it may be inefficiently phosphorylated by TGFBR1, which is sensitive to the sub-optimal dose of SB-431542. The requirement for two distinct type I receptors fits well with what was shown for TGF-β responses in endothelial cells, where ACVLR1 and TGFBR1 were both required ([@bib16]; [@bib17]).

Our optogenetic experiments revealed that activated TGFBR1 phosphorylates and activates ACVR1 in vivo. We previously hypothesized that TGFBR1 and ACVR1 could be in the same receptor complex ([@bib9]), but our use of the mutant TGF-β3 ligands here indicated that these two type I receptors are not part of an obligate heterotetrameric receptor, but rather that TGFBR1, activated by TGFBR2 as a result of TGF-β stimulation can phosphorylate and activate ACVR1 in the membrane as a result of receptor clustering ([Figure 7C](#fig7){ref-type="fig"}). We were surprised to see in our optogenetic experiments that light-induced dimers of the activated kinase domain of TGFBR1 were much more active than the monomeric domains, as this suggests that TGFBR1 is able to autophosphorylate and auto-activate in the absence of type II receptors, if brought into close proximity. In fact, a similar observation was made in early studies using chimeric receptors with the extracellular domain of the erythropoietin receptor and the intracellular domain of constitutively active TGFBR1 ([@bib39]). This chimeric receptor could only mediate a growth arrest after stimulation with erythropoietin, indicating that clustering was important for receptor activity in vivo.

Dynamics of TGF-β-induced pSMAD1/5 signaling {#s3-3}
--------------------------------------------

We and others have observed that in most cell types TGF-β-induced SMAD1/5 phosphorylation is transient compared with SMAD2/3 phosphorylation ([@bib9]; [@bib36]; [@bib74]). Using pSMAD2 as a readout, we previously showed that pSMAD2 levels attenuate over time, and remain at a low steady state level that depends on receptors replenishing the cell surface, for as long as ligand is available ([@bib69]). Our demonstration that levels of fluorescence of the ACVR1-IPF biosensor steadily increase over a number of hours indicates that ACVR1 can also be continuously activated for as long as ligand is present. We have shown that the transience of SMAD1/5 phosphorylation requires new protein synthesis, indicating that SMAD1/5 phosphorylation is likely to be actively terminated by an inhibitor induced by the pathway. Given the prolonged activation of ACVR1-IPF in response to ligand, we hypothesize that such an inhibitor is unlikely to target the receptors, but might be a TGF-β-induced phosphatase that targets phosphorylated SMAD1/5 directly. The transience of SMAD1/5 phosphorylation is not a defining characteristic of this arm of TGF-β signaling as BT-549 breast cancer cells exhibit a more sustained response, which is even more pronounced when the cells are grown as spheres. Comparing TGF-β target genes in BT-549s versus MDA-MB-231s where the response is transient, might shed light on the identity of the putative inhibitor.

TGF-β-induced pSMAD1/5 is transcriptionally active and required for a subset of TGF-β-induced target genes {#s3-4}
----------------------------------------------------------------------------------------------------------

Our ChIP-seq analysis demonstrates for the first time that TGF-β-induced pSMAD1/5 accumulates in the nucleus and binds to chromatin. These experiments revealed that the peaks with the highest pSMAD1/5 enrichment flanked classical BMP target genes, such as *ID1, ID3* and *ATOH8*. Analysis of the binding sites led us to the discovery that the SMAD complexes responsible for inducing these target genes downstream of TGF-β were pSMAD1/5--SMAD4 complexes. The ChIP-seq analysis also revealed widespread co-binding of pSMAD1/5 and SMAD3, which was surprising. For the classical BMP targets, the ratio of pSMAD1/5:SMAD3 in the peaks was high, whereas at classical TGF-β targets like *JUNB, PMEPA1, SERPINE1* and *BHLHE40* ([@bib28]; [@bib33]), this ratio was less than 1. We do not fully understand the functional significance of the pSMAD1/5 and SMAD3 co-binding. We previously demonstrated that at least in some contexts, pSMAD3--pSMAD1/5 complexes are inhibitory ([@bib18]), and this is evident in the work presented here for *ID3* induction. However, for *JUNB* we found that knockdown of SMAD1/5 had no effect on TGF-β-induced transcription, suggesting that pSMAD1/5 is not contributing to its transcriptional regulation. This may also be true of other genes with a similar pattern of SMAD3/pSMAD1/5 binding.

TGF-β-induced SMAD1/5 signaling is required for EMT through induction of ID1 {#s3-5}
----------------------------------------------------------------------------

We have now shown that SMAD1/5 signaling in response to TGF-β is required for a complete TGF-β-induced EMT in NMuMG cells and in EpRas cells. This accounts for a previously unexplained observation that overexpression of dominant negative ACVR1 in NMuMGs caused a partial loss of EMT in response to TGF-β ([@bib45]). In an earlier study using siRNAs we had concluded that the SMAD1/5 arm of the TGF-β pathway was not required for EMT in EpRas cells ([@bib9]). The likely explanation for this discepency is the poor SMAD1/5 knockdown we achieved in those cells compared with the very effective strategy of inhibiting this arm of TGF-β signaling using the combined small molecule inhibitors that we have employed here.

We have gone on to show that TGF-β-induced ID1 is required for EMT. Importantly, although ID1 is necessary for EMT, it is clearly not sufficient, as BMPs cannot induce EMT in NMuMGs ([@bib29]). Consistent with this we have also shown that the SMAD3 pathway is essential for EMT. This arm of the pathway is likely required for the induction of some or all of the so-called EMT-associated transcription factors, most notably SNAI1, SNAI2, ZEB1, ZEB2 and BHLH proteins such as TWIST1 and E47 (now called TCF3), some of which are known direct TGF-β targets ([@bib57]; [@bib11]).

Our finding that EMT depends on TGF-β-induced ID1 expression has implications for the role of SMAD1/5 and the IDs in cancer. The prevailing view is that ID1 is downregulated by TGF-β in non-tumorigenic human epithelial lines, but upregulated by TGF-β in established tumor cell lines, as we have observed here in MDA-MB-231 and BT-549s, and also in patient-derived tumor cells ([@bib1]; [@bib55]; [@bib31]). Furthermore, ID proteins are overexpressed in many different tumor types and are implicated in the maintenance of tumor stem cells and for some cancer-related phenotypes ([@bib31]). ID1 was also found in a lung metastatic gene signature of breast cancer ([@bib47]). The role of ID1 in EMT is context dependent. In a recent study of breast cancer, ID1 was shown to be expressed in tumor cells that had already undergone an EMT, and it contributed to the growth of the primary tumor by inducing a stem cell-like phenotype. At the metastatic site, however, TGF-β-induced ID1 was proposed to induce an mesenchymal-to-epithelial transition (MET) by interferring with the activity of TWIST ([@bib66]). In light of our current data it will be important to investigate in what tumor contexts ID1 is required for EMT, and more broadly how the TGF-β--SMAD1/5 pathway contributes to different aspects of tumorigenesis.

Materials and methods {#s4}
=====================

Cell line origin, authentication and maintenance {#s4-1}
------------------------------------------------

MDA-MB-231 cells were obtained from the ECACC/HPA culture collection, BT-549 cells were obtained from the Francis Crick Institute Cell Services, NMuMG cells were obtained from ATCC, MDCKII cells were obtained from Sigma (UK), NIH-3T3 cells were obtained from Richard Treisman (Francis Crick Institute) and EpRas cells were obtained from Martin Oft and Hartmut Beug (IMP, Vienna). All cell lines have been banked by the Francis Crick Institute Cell Services, and certified negative for mycoplasma. In addition, MDA-MB-231 and BT-549 cells were authenticated using the short tandem repeat profiling, while MDCKII, NIH-3T3 and EpRas cells had species confirmation at the Francis Crick Institute Cell Services. Their identity was also authenticated by confirming that their responses to ligands and their phenotype were consistent with published history.

MDA-MB-231, BT-549, EpRas, NIH-3T3 and MDCKII cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin. NMuMG cells were grown in the same medium, but supplemented with 10 µg/ml insulin. MDA-MB-231 and MDCKII cells were starved overnight in OptiMEM prior to ligand stimulation; NMuMG cells were starved overnight in OptiMEM with 10 µg/ml insulin; NIH-3T3 cells were starved in DMEM with 0.5% FCS. For ligand stimulation experiments, BT-549 cells were plated in the mammosphere culture media ([@bib13]) (MEBM (PromoCell, Germany) with B27 (Thermo Fisher, UK), 20 ng/ml EGF (PeproTech, UK), 20 ng/ml bFGF (PeproTech) and 4 μg/ml heparin (Sigma).

Ligands and chemicals {#s4-2}
---------------------

All recombinant ligands were reconstituted in 4.4 mM HCl supplemented with 0.1% BSA. Cells were treated with recombinant TGF-β1 (PeproTech, 100--21C; 2 ng/ml), BMP4 (PeproTech, 120-05ET; 20 ng/ml) and Noggin (PeproTech, 250--38; 300 ng/ml). TGF-β3^WW^ and TGF-β3^WD^ were as described ([@bib25]). SB-431542 (Tocris, UK) was used at the concentrations indicated, SB-505124 (Tocris) at 10 or 50 µM, LDN-193189 (a gift from Paul Yu) at 1 or 0.5 µM, DMH1 (Selleck Chemicals, Germany) at 1 µM, cyclohexamide (Sigma) at 20 µg/ml and actinomycin D (Sigma) at 1 µg/ml. For TGF-β blocking experiments, the pan-TGF-β blocking antibody (1D11) and the control antibody (13C4) were used at 30 µg/ml ([@bib51]).

CRISPR/Cas9 knockout of SMAD1/5 and ACVR1/BMPR1A in NMuMG cells {#s4-3}
---------------------------------------------------------------

From the wild-type NMuMG cells, a parental clone was selected that expressed robust junctional markers (TJP1 and CDH1) and underwent an efficient EMT in response to TGF-β. Two guide RNAs (see Key Resources Table) targeting the MH1 domain (SMAD1) and MH2 domain (SMAD5) were expressed from the plasmid pSpCas9(BB)−2A-GFP (PX458) ([@bib61]) and used to knock out SMAD1 and SMAD5. NMuMG parental clone cells were simultaneously transfected with both plasmids, sorted for GFP expression, plated as single cells in 96-well plates and screened by sequencing to verify mutations in SMAD1 and SMAD5. Two knockout clones, ΔSMAD1/5 clone 1 and 2, were used in these studies. The same parental clone of NMuMG cells was also used to generate a line knocked out for ACVR1 and BMPR1A. The strategy was as described for the SMAD1/5 knockout and the guides are given in the Key Resources Table.

Generation of cell lines stably expressing ACVR1-IPF {#s4-4}
----------------------------------------------------

The InversePericam FKBP1A (IPF) fusion protein was amplified by PCR from the pCS2+zALK3 IPF ([@bib44]) and cloned in-frame downstream of the human ACVR1 cDNA sequence in the pcDNA3.1 Hygro (+) vector (Thermo Fisher). MDCKII and NIH-3T3 cells were transfected with the ACVR1-IPF construct and selected with 400 µg/ml hygromycin or 40 µg/ml hygromycin, respectively. After selection, cells were FACS sorted for GFP expression. MDCKII ACVR1-IPF cells were maintained as a pool, while a single clone was isolated for NIH-3T3 cells. To test the functionality of ACVR1-IPF, NMuMG cells knocked out for ACVR1 and BMPR1A were transfected with empty pcDNA3.1 Hygro (+), ACVR1-IPF or FLAG-ACVR1 ([@bib9]) as a positive control, and activity was monitored by their ability to induce phosphorylation of SMAD1/5.

Generation and LED light photoactivation of Opto-receptors {#s4-5}
----------------------------------------------------------

The general design of the Opto receptors was as previously described ([@bib64]). Opto-TGFBR1\* and Opto-ACVR1 were generated by overlapping PCR ([@bib24]) to include a N-terminal myristyolation domain, the intracellular domain of either human TGFBR1 (residues 149--503) or human ACVR1 (residues 147--509), a light-oxygen-voltage (LOV) domain from *Vaucheria frigida* ([@bib68]) and a C-terminal HA-tag and cloned into the pCS2 expression plasmid (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). In the case of TGFBR1, the T204D point mutation was introduced that renders the kinase constitutively active ([@bib72]), thus generating the construct Opto-TGFBR1\*. A kinase dead version of Opto-TGFBR1 was also generated in which K232 was mutated to R ([@bib73]). Furthermore, the GS-domain of ACVR1 (^189^TSGSGS^194^) was mutated to VAGAGA to generate Opto-ACVR1 GS-mut. NIH-3T3 cells were transfected with a total of 2 μg of plasmid DNA that included either 5 ng of GFP-SMAD3 ([@bib52]) or 25 ng of Flag-SMAD1 ([@bib32]) alone or in combination with 25 ng of Opto-TGFBR1\* and/or 50 ng of Opto-ACVR1 (WT or GS-mut). We co-transfected the SMADs with the Opto-receptors to increase the range of the assay. Twenty-four hours post-transfection, cells were starved overnight in DMEM with 0.5% FCS. Cells were then left untreated or pre-treated with 0.5 μM LDN-193189 or 50 μM SB-505124 and then exposed to blue light from an LED array for 1 hr at 37°C in a humidified incubator. Control cells (i.e. in the dark) were wrapped in aluminium foil and placed in the same incubator.

siRNAs and transfections {#s4-6}
------------------------

All siRNAs were purchased from Dharmacon/GE Health Care Life Sciences (UK) and are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. MDA-MB-231 and NMuMG cells were transfected with siRNAs at a final concentration of 20 nM with Interferin (Polyplus, France). Twenty four hours post-transfection, cells were starved overnight, and the following day cells were treated with TGF-β or BMP4 for 1 hr and RNA and/or protein extracted. NMuMG cells were also treated with TGF-β for a further 24--48 hr to assess the effects of target gene knockdown on EMT.

EMT assay {#s4-7}
---------

NMuMG or EpRas cells were plated on glass coverslips in six-well plates (200,000 or 75,000 cells, respectively). For NMuMG cells treated with small molecule inhibitors, the media was changed the day after plating to OptiMEM with 10 µg/ml insulin and the cells treated with 2 ng/ml TGF-β alone or in combination with 0.125 µM SB-431542, 1 µM LDN-193189 or DMH1 for the durations indicated. For knockdown experiments, NMuMG cells were transfected the day after plating with the indicated siRNAs. Twenty-four hours after transfection, the media was changed to OptiMEM with 10 µg/ml insulin and the following day, cells were treated with TGF-β for the durations indicated. For EpRas, cells were treated with 2 ng/ml TGF-β alone or in combination with 0.125 µM SB-431542 and 1 µM LDN-193189 the day after plating. EpRas cells were then split and re-plated at the initial splitting density in the presence of 2 ng/ml TGF-β alone or in combination with SB-431542 and LDN-193189 every 3 days.

Antibodies, immunoblotting, immunoprecipitations and indirect immunofluorescence {#s4-8}
--------------------------------------------------------------------------------

All primary and secondary antibodies used are listed in the Key Resources Table. Western blots using whole cell extracts and immunoprecipitations followed by western blotting were as previously described ([@bib15]; [@bib9]). Indirect immunofluorescence of the ACVR1-IPF was performed after fixing cells in 4% formaldehyde for 5 min. Indirect immunofluorescence for CDH1 and TJP1 was performed after fixation in methanol:acetone (1:1) as previously described ([@bib53]). Nuclei were counter stained with DAPI (0.1 µg/ml). Imaging was performed on a Zeiss Upright 780 confocal microscope. Z-stacks were acquired for all channels and maximum intensity projection images are shown.

Live cell imaging {#s4-9}
-----------------

Live cell imaging was performed for MDCKII ACVR1-IPF and NIH-3T3 ACVR1-IPF cells on a Zeiss Invert 780 confocal microscope. Cells were plated on 35 mm MatTek dishes (MatTek, Ashland, MA, USA) and starved overnight in phenol-free, HEPES-buffered DMEM with 0.5% FCS. During imaging, the temperature was maintained at 37°C. Data were acquired every 15 min over a time course. At each time point, a z-stack was acquired, and maximum intensity z-projections were quantified with ImageJ.

Flow cytometry {#s4-10}
--------------

MDCKII ACVR1-IPF and NIH-3T3 ACVR1-IPF cells were treated with ligand ± inhibitors. Twenty four hours post treatment, cells were trypsinized, washed and analyzed for GFP/YPF fluorescence on a LSRII flow cytometer (BD Biosciences, San Jose, CA, USA), gated for viable, single cells. Treatment with FK506 (Sigma) was performed for 4 hr prior to analysis.

Recombinant proteins, in vitro kinase assays and mapping of phospho-sites {#s4-11}
-------------------------------------------------------------------------

Recombinant SMAD proteins were expressed in *E. coli* and purified as previously described ([@bib63]). Recombinant intracellular domains of ACVR1, BMPR1A and TGFBR1 which were expressed in insect cells were purchased from Carna Biosciences Inc (Japan; see Key Resources Table). Radioactive kinase reactions were performed with varying amounts of receptor (25--200 ng) at 37°C for 1 hr in a 20 µl reaction volume with 50 mM Tris-Cl (pH 7.5), 50 mM NaCl, 5 mM MnCl~2~ (ACVR1 and TGFBR1) or MgCl~2~ (BMPR1A), 16.5 nM ^32^P-γ-ATP (Perkin Elmer, UK; NEG502A500UC) and either 200 µM or 50 µM cold ATP. Substrates were either the receptors themselves (autophosphorylation) or 2 µg of recombinant SMAD proteins. Reactions were stopped by adding Laemmli sample buffer and heating to 95°C for 5 min. Proteins were resolved on a NuPAGE Novex 4--12% Bis-Tris gradient gel (Thermo Fisher) and stained with Colloidal Blue (Thermo Fisher). Gels were destained, dried and radioactivity measured by autoradiography.

To map phosphorylated residues on SMAD1, radioactive kinase reactions were performed in triplicate with 200 ng ACVRI, 2 µg recombinant SMAD1, 200 µM cold ATP, 0.33 µM ^32^P-γ-ATP. For phospho-residue mapping, ^32^P-labeled SMAD1 was digested with trypsin, the peptides were resolved by HPLC with an acetonitrile gradient and the ^32^P-labeled peptides eluted. Edman sequencing and mass-spectrometry (Orbitrap Classic, Thermo Fisher) were then used to confirm phospho-residues, as described previously ([@bib4]), with the addition of multi-stage activation during the MS2 analysis.

Chromatin immunoprecipitations, ChIP-Seq and motif enrichment {#s4-12}
-------------------------------------------------------------

Four million MDA-MB-231 or BT-549 cells were plated; 24 hr later, cells were starved overnight and the following day treated with TGF-β or BMP4. One 15 cm plate was used per immunoprecipitation. Chromatin immunoprecipitations, ChIP-seq library preparation, next generation sequencing and data analysis were performed in biological duplicate essentially as previously described ([@bib6]). In brief, ChIP-seq was performed on an Illumina HiSeq2500 (Illumina, San Diego, CA, USA) generating 50 bp single end reads. Reads were aligned to the human GRCh37/hg19 genome assembly using BWA version 0.6 ([@bib35]) with a maximum mismatch of 2 bases. Picard tools version 1.81 (<http://sourceforge.net/projects/picard/>) was used to sort, mark duplicates and index the resulting alignment bam files. Normalized tdf files for visualization purposes were created using IGVtools software ([@bib62]) (<http://software.broadinstitute.org/software/igv/>) by extending reads by 50 bp and normalizing to 10 million mapped reads per sample. Peaks were called by comparing stimulated samples to the respective untreated samples using MACS version 1.4.2 ([@bib78]), using mfold change parameters of between 5 and 30. Peaks called by MACS were annotated using the annotatepeaks command in the Homer software ([@bib21]) (<http://homer.salk.edu/homer/>).

Peaks with less than 20 tags in the pSMAD1/5 IP after TGF-β treatment or less than 30 tags in the SMAD3 IP after TGF-β treatment were excluded from the analysis. In addition, peaks that had less than 1 tag per 10 bp in either of the above conditions were also excluded. Finally a ratio was taken between the number of tags in the pSMAD1/5 IP and the number of tags in the SMAD3 IP after TGF-β treatment to determine the top 100 peaks with preferential SMAD1/5 binding. Of these, the top 50 peaks with the highest density of tags per 10 bases in the pSMAD1/5 IP after TGF-β treatment were used for more refined motif enrichment analysis and gene annotation.

Motif enrichment was performed using MEME (<http://meme-suite.org/>) with default parameters (zero or one occurrence per sequence, motifs between 6 and 50 bases in width).

RNA-sequencing analysis in the NMuMG parental clone and ΔSMAD1/5 clone 1 {#s4-13}
------------------------------------------------------------------------

NMuMG parental and ΔSMAD1/5 clone 1 were plated, starved the next day in OptiMEM with 10 µg/ml insulin and treated for a further 48 hr with 2 ng/ml TGF-β. Total RNA was extracted as previously described ([@bib18]), DNase I (Qiagen, Germany) treated and cleaned up with RNeasy columns (Qiagen). Biological triplicate libraries were prepared using the TruSeq RNA Library Prep Kit (Illumina) and were single-end sequenced on an Illumina HiSeq 2500 platform. Sequencing yield was typically \~80 million strand-specific reads per sample. The RSEM package (version 1.2.31) ([@bib34]) in conjunction with the STAR alignment algorithm (version 2.5.2a) ([@bib12]) was used for the mapping and subsequent gene-level counting of the sequenced reads with respect to Ensembl mouse GRCm.38.86 version genes. Normalization of raw count data and differential expression analysis was performed with the DESeq2 package (version 1.10.1) ([@bib38]) within the R programming environment (version 3.2.3) ([@bib60]). Genes were first identified as differentially expressed in the parental clone if they had more than 10 reads in either the untreated or TGF-β treated samples and a fold change between untreated and TGF-β induced of \> 1.5 or \< 0.75 and FDR \< 0.05. An interaction contrast was then used to determine differentially regulated genes after TGF-β treatment in the parental clone versus ΔSMAD1/5 clone 1. The resulting gene lists ranked by the Wald statistic were used to look for pathway and biological process enrichment using the Broad's GSEA Tool ([@bib67]). Genes with a fold difference between the two clones after TGF-β treatment of \> 1.5 or \< 0.75 and an FDR \< 0.05 were judged to be dependent on SMAD1/5.

Public availability of data {#s4-14}
---------------------------

The ChIP-seq data have been submitted to the NCBI Gene Expression Omnibus (GEO) under the accession number GSE92443. The RNA-seq data has been submitted to GEO under the accession number GSE103372.

qPCR {#s4-15}
----

Oligonucleotides used are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. Total RNA extraction and reverse transcription were performed as previously described ([@bib18]). The cDNA was diluted 10-fold and then used for quantitative PCR (qPCR). All qPCRs were performed with Express Sybr Greener (Thermo Fisher) with 300 nM of each primer and 2 µl of diluted cDNA or eluted immunoprecipitated chromatin. Fluorescence acquisition was performed on a 7500 FAST machine (Thermo Fisher). Quantification for relative gene expression was done using the comparative Ct method with target gene expression normalized to *GAPDH*. Quantification for ChIPs was performed using a standard curve and presented normalized to input.

Statistical analysis {#s4-16}
--------------------

Western blots, immunofluorescence experiments and ChIP-PCRs are representative of at least two biological replicate experiments. All qPCRs are the mean and SEM of three independent biological experiments except gene expression after actinomycin D treatment and stimulation with TGF-β3^WW^ and TGF-β3^WD^ and validation of RNA-sequencing results that are a representative of two independent experiments. Statistical analyses were performed with the unpaired Students T-Test, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, ns, non significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Philip Cole as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a compelling study that demonstrates a role for ACVR1 in the activation of Smad1/5 by TGFbeta. The mechanism is reported to be mediated by TGFBR1 mediated phosphorylation and activation of ACVR1. The authors show that the Smad1/5 arm of the TGF β signaling pathway leads to the regulation of a fraction of the total TGF β responsive genes. Moreover, the authors associate this gene expression program with EMT. In conclusion, this is an excellent, well written manuscript that provides compelling evidence to explain a known paradox in TGFB signaling, the transient induction of pSMAD1/5, and shows that it is biologically important.

Essential revisions:

1\) While 10 µM SB inhibits both pSmad1/5 and pSmad2, and 0.25 μm still inhibits both but possibly inhibiting more pSmad1/5 than pSmad2 (no quantification done), it is too strong to conclude that TGFBR1 is differentially required for SMAD1/5 versus SMAD2 phosphorylation. More evidence is required before such a conclusion can be made.

2\) [Figure 2C](#fig2){ref-type="fig"}. Since TGFBR1 opto-activation alone can robustly induce phosphorylation of SMAD1, it cannot be concluded that TFGBR1 + ACVR1 opto-activation of pSMAD1 is by TGFBR1 activating ACVR1. This conclusion in the Discussion section, and in the Abstract (possibly elsewhere) should not be made based on these results.

3\) Is ACVR1-IPF functional? The cells used already induce pSMAD1 in response to TGFB treatment -- the endogenous receptors are therefore functional.

4\) The authors speculate in the Discussion that the prolonged fluorescence of ACVR1-IPF reflects continued activation of ACRV1 in the absence of pSMAD1 and that a phosphatase likely dephosphorylates pSMAD1 in this system. Do the authors know that the ACVR1-IPF conformation change of cpYFP is reversible in their system? Perhaps ACVR1 can no longer be activated, but cpYFP fluorescence persists?

5\) The optogenetic studies ([Figure 2](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}) require a control using a TGFBR1 kinase dead mutant to show that TGFBR1 kinase activity is required for the activation of ACVR1. This is necessary to exclude the possibility that ACVR1 activation is mediated by conformational interactions alone.

6\) [Figure 2E](#fig2){ref-type="fig"} and subsection "ACVR1 is activated by TGFBR1 in vitroand in vivo*"*: Light-inducible FLAG-Smad1 phosphorylation was reduced when the GS domain mutant of Opto-ACVR1 was used instead of Opto-ACVR1, but light-inducible endogenous Smad1 phosphorylation was not ([Figure 2E](#fig2){ref-type="fig"}, four lanes at the right side). In addition, co-expression of Opto-ACVR1 with Opto-TGFR1\* failed to affect endogenous Smad1 phosphorylation. These results do not support the authors\' conclusion. Why was co-transfected FLAG-Smad1 used in these studies since activation of the BMP type I receptor can be monitored by endogenous Smad1.

7\) It has been shown that TGFB-WD cannot bind TGFBR1 or R2, but can it bind ACVR1? Has this been tested? If it has not been tested, then it is possible that TBR1 and ACVR1 are in the same complex.

8\) Conflicts with an earlier study: Daly et al., (2008). [Figure 5A](#fig5){ref-type="fig"}, subsection "Mapping the binding sites on chromatin for TGF-b-induced pSMAD1/5 reveals that *ID* genes are major transcriptional targets of this pathway" and subsection "Combinatorial signaling downstream of TGF-β": The authors previously reported that TGF-b-induced Smad1/5 phosphorylation does not lead to transcriptional activation via BMP-responsive element, because Smad2/3-Smad1/5 mixed complexes are formed. In addition, they stated that Smad1 coimmunoprecipiated with Smad4 only after stimulation with BMP-4 but not TGF-b in EpH4 cells (Daly et al., 2008). Now they present data in which TGF-b induces formation of a Smad1/5-Smad4 complex. This is also confusing to readers. They should mention and discuss their previous results in the main text.

[Figure 6B](#fig6){ref-type="fig"}: The authors previously reported that knockdown of Smad1/5 did not affect TGF-b-induced EMT in EpRas cells (based on cell morphology and mesenchymal marker expression) (Daly et al., 2008). Now they state that knockout of Smad1/5 inhibited TGF-b-induced EMT in NMuMG cells (based on localization of ZO-1 and E-cadherin). This is quite confusing to readers. Localization of ZO-1 and E-cadherin was partially disrupted and cell morphologies were changed by TGF-b in Smad1/5 knockout cells ([Figure 6B](#fig6){ref-type="fig"}, compare with [Figure 7A](#fig7){ref-type="fig"}). The present statement is thus misleading. Only a subset of the EMT processes appears to be affected by loss of Smad1/5. At least, expression of epithelial as well as mesenchymal markers should be examined.

10.7554/eLife.31756.054

Author response

> Essential revisions:
>
> 1\) While 10 µM SB inhibits both pSmad1/5 and pSmad2, and 0.25 μm still inhibits both but possibly inhibiting more pSmad1/5 than pSmad2 (no quantification done), it is too strong to conclude that TGFBR1 is differentially required for SMAD1/5 versus SMAD2 phosphorylation. More evidence is required before such a conclusion can be made.

The reviewer is correct that we cannot conclude that TGFBR1 is differentially required for SMAD1/5 versus SMAD2 phosphorylation based solely on the observation that the low dose of SB-431542 inhibits phosphorylation of SMAD1/5 more effectively than SMAD2 phosphorylation. We have now removed this sentence (see subsection "TGF-β-induced SMAD1/5 phosphorylation requires the kinase activity of two different type I receptors").

The main aim of using the drugs was to establish conditions where we could inhibit TGF-β-induced phosphorylation of SMAD1/5, whilst having a minimal effect on SMAD2 phosphorylation. We show this in three different cells lines (in MDA-MB-231s ([Figure 1D](#fig1){ref-type="fig"}); in NMuMGs ([Figure 6---figure supplement 3E](#fig6s3){ref-type="fig"}) and in EpRas cells ([Figure 6F](#fig6){ref-type="fig"}) using a combination of LDN-193189 and low dose SB-431542 (either 0.25 µM or 0.125 µM depending on the cell line).

The reviewers are referring specifically to the result in the MDA-MB-231 cells ([Figure 1D](#fig1){ref-type="fig"}), where it is evident that the 0.25 µM SB-431542 alone did have a small inhibitory effect on SMAD2 phosphorylation, although a stronger effect on SMAD1/5 phosphorylation. Because the quality of the original pSMAD2 blot was not very high, we have now re-done this experiment and replaced the panel (see new [Figure 1D](#fig1){ref-type="fig"}). In the new Figure it is clear that the 0.25 µM SB-431542 dose does have a small effect on pSMAD2 levels, but a stronger effect on pSMAD1/5 levels. In combination with LDN-193189 it is sufficient to completely inhibit pSMAD1/5, whilst having no additional effect on pSMAD2.

Given that we show the result in three different cell lines, we consider that the result in robust and the conclusion is valid.

> 2\) [Figure 2C](#fig2){ref-type="fig"}. Since TGFBR1 opto-activation alone can robustly induce phosphorylation of SMAD1, it cannot be concluded that TFGBR1 + ACVR1 opto-activation of pSMAD1 is by TGFBR1 activating ACVR1. This conclusion in the Discussion section, and in the Abstract (possibly elsewhere) should not be made based on these results.

The ability of activated Opto-TGFBR1\* to induce phosphorylation of SMAD1 in response to light was unexpected. However, because we were able to show that this SMAD1 phosphorylation was inhibited by both SB-505124 (which inhibits TGFBR1) and LDN-193189 (which only inhibits the BMP type I receptors), we were confident concluding that this resulted from the light induced TGFBR1\* activating endogenous ACVR1 (and possibly also BMPR1A/B), which then phosphorylate SMAD1. Importantly, when we combined Opto-TGFBR1\* with Opto-ACVR1 (which has no activity on its own) we saw a robust increase in SMAD1 phosphorylation, as the exogenous FLAG-SMAD1, that we added to increase the range of the assay, was strongly phosphorylated.

We have now optimized the assay conditions further and have realised that the amount of SMAD1 phosphorylation that we see with Opto-TGFBR1\* alone is dependent on the amount of this receptor transfected and also on the transfection efficiency of the experiment. We have now repeated the experiments and present the new data in [Figure 2C, D](#fig2){ref-type="fig"} and E. In these conditions there is minimal phosphorylation of SMAD1 when Opto-TGFBR1\* is used alone, but robust phosphorylation when used together with Opto-ACVR1. Taking these results together with the IPF results ([Figure 4](#fig4){ref-type="fig"}) and the in vitro phosphorylation results ([Figure 2A](#fig2){ref-type="fig"}), we are confident that we can conclude that TGFBR1 activates ACVR1 that phosphorylates SMAD1/5.

> 3\) Is ACVR1-IPF functional? The cells used already induce pSMAD1 in response to TGFB treatment -- the endogenous receptors are therefore functional.

This is a very valid point. We know that it is activated in response to ligand, and we can see it being internalised into vesicles (evident in the Videos), but we had not demonstrated that it can phosphorylate SMAD1/5 downstream.

To do this cleanly we needed a cell line null for ACVR1 and BMPR1A. We have now generated such a line in NMuMGs using CRISPR/Cas9. Transfection of the ACVR1-IPF results in phosphorylation of SMAD1/5 (see new [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} and subsection "TGF-β induces ACVR1 activation in vivoin a TGFBR1-dependent manner"). Thus, we can conclude that the ACVR1-IPF is active.

> 4\) The authors speculate in the Discussion that the prolonged fluorescence of ACVR1-IPF reflects continued activation of ACRV1 in the absence of pSMAD1 and that a phosphatase likely dephosphorylates pSMAD1 in this system. Do the authors know that the ACVR1-IPF conformation change of cpYFP is reversible in their system? Perhaps ACVR1 can no longer be activated, but cpYFP fluorescence persists?

The reviewers raise a very valid point. We do not think that the conformation change of cpYFP is reversible in our system. As we observe that the levels of fluorescence continue to accumulate over time when the cells are stimulated with ligand and does not plateau, we conclude that new surface receptor is continuously being activated during the course of the experiment.

> 5\) The optogenetic studies ([Figure 2](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}) require a control using a TGFBR1 kinase dead mutant to show that TGFBR1 kinase activity is required for the activation of ACVR1. This is necessary to exclude the possibility that ACVR1 activation is mediated by conformational interactions alone.

We have now done this control and show the results in new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. The results show that the kinase-dead Opto-TGFBR1 has no activity in this assay at all. This result complements the experiment we had already done showing that we can inhibit the light-induced phosphorylation of SMAD1/5 by Opto-TGFBR1\* and Opto-ACVR1 with the TGFBR1 inhibitor SB-505124 (see new [Figure 2C](#fig2){ref-type="fig"}).

*6) [Figure 2E](#fig2){ref-type="fig"} and subsection "ACVR1 is activated by TGFBR1* in vitro *and* in vivo*": Light-inducible FLAG-Smad1 phosphorylation was reduced when the GS domain mutant of Opto-ACVR1 was used instead of Opto-ACVR1, but light-inducible endogenous Smad1 phosphorylation was not ([Figure 2E](#fig2){ref-type="fig"}, four lanes at the right side). In addition, co-expression of Opto-ACVR1 with Opto-TGFR1\* failed to affect endogenous Smad1 phosphorylation. These results do not support the authors\' conclusion. Why was co-transfected FLAG-Smad1 used in these studies since activation of the BMP type I receptor can be monitored by endogenous Smad1.*

We used FLAG-SMAD1 in the assays because, in our experience of overexpression of wild type receptors in many different cell lines, we had previously found that they rarely phosphorylated endogenous SMADs very well and were much better assayed by co-transfecting the substrate SMAD, possibly because of relatively low transfection efficiency. (For a nice example of this see [Figure 7A](#fig7){ref-type="fig"} in Randall et al., (2004)). However, initial experiments indicated that we could see some phosphorylation of endogenous SMAD1/5 by the Opto receptors, but we retained the FLAG-SMAD1 in the assay as it substantially extends the range of the assay. This is now mentioned in the text (see subsection "ACVR1 is activated by TGFBR1 in vitroand in vivo" and subsection "Generation and LED light photoactivation of Opto-receptors").

As explained under point 2, we have now found conditions where the Opto-TGFBR1\* alone has little effect on SMAD1/5 phosphorylation, but when combined with Opto-ACVR1 can induce robust phosphorylation upon light induction. This is predominantly seen as phosphorylation of the FLAG-SMAD1 and the result is very clear (new [Figure 2C and D](#fig2){ref-type="fig"}).

We have not redone the GS domain experiment as we consider that the result was clear, in that we can show that the phosphorylation of FLAG-SMAD1 that results from Opto-ACVR1 in the presence of Opto-TGFBR1\* is dependent on the presence of an intact GS domain. Note that the Opto-TGFBR1\*-induced phosphorylation of endogenous SMAD1 by light in this experiment will obviously not be inhibited when we use the Opto-ACVR1 GS domain mutant, as it is mediated by endogenous BMP type I receptors (see explanation under point 2).

> 7\) It has been shown that TGFB-WD cannot bind TGFBR1 or R2, but can it bind ACVR1? Has this been tested? If it has not been tested, then it is possible that TBR1 and ACVR1 are in the same complex.

Just to clarify, the mutations in the TGF-β3 D subunit render it unable to bind TGFBR1 or TGFBR2. However, the TGF-β3 WD heterodimer obviously can bind these receptors, as it does so through the wild type subunit (TGF-β3 W) binding a type I/type II dimer. This is the essence of Huang et al., 2011 paper that we refer to.

With reference to the possibility that TGF-β3 WD might bind ACVR1. Studies from the Hinck lab a number of years ago showed that TGF-β3 WW cannot bind ACVR1. Given this, it is extremely unlikely that the mutated D subunit, which was designed to abolish receptor binding (to TGFBR1 or TGFBR2), would be able to bind ACVR1. This is now mentioned in the text (see subsection "TGF-β leads to clustering of ACVR1 and TGFBR1").

> 8\) Conflicts with an earlier study: Daly et al., (2008). [Figure 5A](#fig5){ref-type="fig"}, subsection "Mapping the binding sites on chromatin for TGF-b-induced pSMAD1/5 reveals that ID genes are major transcriptional targets of this pathway" and subsection "Combinatorial signaling downstream of TGF-β": The authors previously reported that TGF-b-induced Smad1/5 phosphorylation does not lead to transcriptional activation via BMP-responsive element, because Smad2/3-Smad1/5 mixed complexes are formed. In addition, they stated that Smad1 coimmunoprecipiated with Smad4 only after stimulation with BMP-4 but not TGF-b in EpH4 cells (Daly et al., 2008). Now they present data in which TGF-b induces formation of a Smad1/5-Smad4 complex. This is also confusing to readers. They should mention and discuss their previous results in the main text.

We are sorry for the confusion. The reviewer is correct. In our 2008 paper we were unable to detect any complexes between SMAD1/5 and SMAD4 in response to TGF-β in EpH4 cells, and we thought that this explained why the BMP responsive element (BRE) could not be activated in response to TGF-β. In a subsequent study (Gronroos et al., 2012) we could detect a low level of SMAD1/4--SMAD4 complexes by IP in MDA-MB-231 cells (see [Figure 5A](#fig5){ref-type="fig"} in that paper) and showed that the inability of TGF-β to activate the BRE was actually dependent on SMAD3 ([Figure 7C](#fig7){ref-type="fig"} in Gronroos et al.,). We concluded that a complex comprising pSMAD1/5 and pSMAD3 inhibits the activity of the BRE.

Upon further optimization of the IPs, we can now show clearly that TGF-β can induce pSMAD1/5--SMAD4 complexes as well as pSMAD2/3--SMAD4 and pSMAD2/3--pSMAD1/5 complexes in MDA-MB-231 cells (see [Figure 5A](#fig5){ref-type="fig"} in current paper).

We have amended the text to mention our previous work (see subsection "Mapping the binding sites on chromatin for TGF-β-induced pSMAD1/5 reveals that *ID* genes are major transcriptional targets of this pathway**"**).

> [Figure 6B](#fig6){ref-type="fig"}: The authors previously reported that knockdown of Smad1/5 did not affect TGF-b-induced EMT in EpRas cells (based on cell morphology and mesenchymal marker expression) (Daly et al., 2008). Now they state that knockout of Smad1/5 inhibited TGF-b-induced EMT in NMuMG cells (based on localization of ZO-1 and E-cadherin). This is quite confusing to readers. Localization of ZO-1 and E-cadherin was partially disrupted and cell morphologies were changed by TGF-b in Smad1/5 knockout cells ([Figure 6B](#fig6){ref-type="fig"}, compare with [Figure 7A](#fig7){ref-type="fig"}). The present statement is thus misleading. Only a subset of the EMT processes appears to be affected by loss of Smad1/5. At least, expression of epithelial as well as mesenchymal markers should be examined.

Again, we are sorry for the confusion. In our previous work in 2008 in EpRas cells, we got rather inefficient knockdown of SMAD1/5 by siRNAs and could not reproducibly show an effect on TGF-β-induced EMT. We reported this as data not shown. Now, with the use of the drug combinations in these EpRas cells (note that LDN-193189 was not available in 2008), we can clearly show that TGF-β-induced SMAD1/5 is required for a full EMT. We have also shown this in NMuMG cells using CRISPR to knock out SMAD1/5, siRNAs and also the drug combinations. We now mention this in the text (see subsection "TGF-β-induced SMAD1/5 signaling is required for EMT through induction of ID1").

We have now stressed in the text that SMAD1/5 is required for a full EMT (see subsection "Combinatorial signaling downstream of TGF-β"). The reviewer is right in that ZO-1 and E-cadherin are partially disrupted upon TGF-β stimulation in the SMAD1/5 knockout cells and cell morphologies were changed.

We agree that it is important to show some mesenchymal genes as well as epithelial ones. In our RNA-seq of the wild type versus SMAD1/5 knockout NMuMG cells we observed a lower induction of *Acta2* (smooth muscle actin) and *Fn1* in the knockout cells relative to the wild type. These genes are highlighted now in red in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, Sheet 2 and we have validated the result by qPCR (see new [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Also note that EMT came up as a relevant pathway when comparing the TGF-β-induced transcriptome of wild type and SMAD1/5 knockout cells (see [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, Sheet 3).

[^1]: Center for Genomic Regulation, Barcelona, Spain.

[^2]: Flow Cytometry, The Francis Crick Institute, London, United Kingdom.
